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Abstract
Background Diagnosis of primary ciliary dyskinesia (PCD) is challenging since there is no gold standard
test. The European Respiratory (ERS) and American Thoracic (ATS) Societies developed evidence-based
diagnostic guidelines with considerable differences.
Objective We aimed to compare the algorithms published by the ERS and the ATS with each other and
with our own PCD-UNIBE algorithm in a clinical setting. Our algorithm is similar to the ERS algorithm
with additional immunofluorescence staining. Agreement (Cohen’s κ) and concordance between the three
algorithms were assessed in patients with suspicion of PCD referred to our diagnostic centre.
Results In 46 out of 54 patients (85%) the final diagnosis was concordant between all three algorithms (30
PCD negative, 16 PCD positive). In eight patients (15%) PCD diagnosis differed between the algorithms.
Five patients (9%) were diagnosed as PCD only by the ATS, one (2%) only by the ERS and PCD-UNIBE,
one (2%) only by the ATS and PCD-UNIBE, and one (2%) only by the PCD-UNIBE algorithm.
Agreement was substantial between the ERS and the ATS (κ=0.72, 95% CI 0.53–0.92) and the ATS and
the PCD-UNIBE (κ=0.73, 95% CI 0.53–0.92) and almost perfect between the ERS and the PCD-UNIBE
algorithms (κ=0.92, 95% CI 0.80–1.00).
Conclusion The different diagnostic algorithms lead to a contradictory diagnosis in a considerable
proportion of patients. Thus, an updated, internationally harmonised and standardised PCD diagnostic
algorithm is needed to improve diagnostics for these discordant cases.
Introduction
Primary ciliary dyskinesia (PCD) is a rare genetic disease with an incidence of 1:10 000 to 1:15 000 in
Europe [1]. To date genetic variants in ∼50 genes are known to cause PCD [2], mainly with defects in
motile cilia of the respiratory epithelium and spermatic flagella [3]. This leads to phenotypic variability
with situs inversus and infertility found frequently [4]. Clinical symptoms mostly start during the neonatal
period including neonatal respiratory distress, chronic wet cough, perennial rhinosinusitis, recurrent
respiratory tract infections leading to bronchiectasis and serous otitis media with hearing impairment [3, 4].
The diagnosis of PCD is challenging since there is no “gold standard” test [7, 8]. Currently, the diagnosis
requires a combination of different investigations: nasal nitric oxide (nNO) flow measurement, ciliary
Copyright ©The authors 2021
This version is distributed under
the terms of the Creative
Commons Attribution Non-




This article has supplementary
material available from
openres.ersjournals.com
Received: 26 May 2021
Accepted: 26 July 2021
https://doi.org/10.1183/23120541.00353-2021 ERJ Open Res 2021; 7: 00353-2021
ERJ OPEN RESEARCH
ORIGINAL RESEARCH ARTICLE
M. NUSSBAUMER ET AL.
motion analysis by high-speed videomicroscopy (HSVM), ciliary (ultra)structure analysis by transmission
electron microscopy (TEM) and immunofluorescence staining, and genetic analysis. Additionally, air–
liquid-interface (ALI) cell cultures can be helpful to differentiate PCD from secondary dyskinesia [3, 5, 6].
However, these methods require high levels of expertise, are expensive and their availability varies among
diagnostic centres even within a country.
Both the European Respiratory Society (ERS) in 2017 [5] and the American Thoracic Society (ATS) in
2018 [7] published guidelines suggesting diagnostic algorithms. However, these guidelines suggest
different diagnostic approaches [8]. The evidence-based ERS guideline focuses on using nNO, HSVM,
TEM and genetic testing and distinguishes four diagnostic categories: i) PCD positive (biallelic pathogenic
or likely pathogenic variants in a PCD-associated gene or hallmark TEM defect); ii) PCD highly likely
(suggestive HSVM and low nNO); iii) PCD highly unlikely; and iv) inconclusive (“consider additional
testing and recall patients for testing as new methods become available”) [5, 9]. In contrast, the ATS
consensus statement focuses on nNO measurement as primary analysis, followed by genetic panel testing
(>12 genes) and TEM. Final categories for this algorithm are: (i) PCD diagnosed and (ii) PCD not
diagnosed. Both algorithms have been compared theoretically [8, 10, 11], but a direct comparison using
clinical data has not been done yet. In our study, we thus aimed to compare final diagnoses according to
these two existing PCD diagnostic algorithms and compare them to the outcome according to the
diagnostic algorithm used at our PCD-UNIBE diagnostic centre in a clinical setting using patients’ data.
Methods
Study design
This study compares the outcome of PCD diagnostic testing according to three different diagnostic
algorithms – the ERS, the ATS and our centre’s (PCD-UNIBE) algorithm (figure 1). We included all
patients referred to our comprehensive PCD-UNIBE diagnostic centre at the University Children’s
Hospital, Inselspital Bern, Switzerland between January 2018 and December 2020 with sufficient data to
allow for a conclusive decision on PCD diagnosis based on all three algorithms. Specifically, we included
only patients with detailed data on clinical symptoms (all categories of the ATS algorithm), nNO of
sufficient quality, and HSVM and immunofluorescence results (not performed for one patient since ciliary
beating pattern in HSVM was normal and the clinical suspicion was low). HSVM after cell culture was
performed if the cells grew successfully; TEM and genetics were performed if required for a decision
based on the PCD-UNIBE algorithm. The study was approved by the Ethics Committee of the Canton
Bern, Switzerland (reference number 2018-02155). We obtained written informed consent from all
participants or their parents.
Diagnostic algorithm of the PCD-UNIBE centre
Description of the algorithm and definition of a positive PCD diagnosis
We developed a new diagnostic algorithm at the PCD-UNIBE diagnostic centre (figure 1 and figure 2)
applied to all patients referred for PCD diagnosis. It is based on the ERS task force guideline for PCD
diagnosis [5] and the international consensus guideline for reporting TEM results (BEAT-PCD TEM
criteria) [12], additionally including immunofluorescence [13] and ALI cell culture as standard procedure
for all brushing samples [14, 15]. Basic investigations are identical for each patient and include nasal
brushing with HSVM (fresh and ALI) and immunofluorescence (preferably from ALI cell cultures).
Depending on clinical presentation [16] and the results of the basic investigations, we additionally consider
TEM and further immunofluorescence stainings. Genetic analysis is done for each patient with a high
clinical suspicion, even if the results of the other methods were non-suggestive. An interdisciplinary
diagnostic board including clinicians, diagnostic research specialists and lab technicians makes decisions
on supplementary investigations.
Results concerning PCD diagnosis are interpreted as follows (figure 2): patients with a class 1 (hallmark)
TEM defect and/or biallelic pathogenic or likely pathogenic variants in PCD-associated genes are
diagnosed as “PCD positive” [5, 12]. Patients with a PCD-suggestive HSVM, a structural protein missing
in immunofluorescence and/or a TEM class 2 defect result are given the diagnosis “PCD highly likely”.
Patients with no suggestive findings in either method are classified as “PCD highly unlikely” and patients
who refuse further needed testing or when further testing is not possible are classified “inconclusive”.
In our study, we consider the categories “PCD positive” and “PCD highly likely” of the ERS and the
PCD-UNIBE algorithms and the category “PCD diagnosed” of the ATS algorithms as confirmed PCD.
Clinically, all confirmed PCD cases are treated equally. Further, we consider the diagnostic outcome “PCD
highly unlikely” of the ERS and the PCD-UNIBE algorithms and “PCD not diagnosed” of the ATS
algorithm as PCD excluded, even though we are aware that PCD can never be formally excluded.
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Diagnostic methods
Nasal nitric oxide (nNO) measurement
nNO is measured according to international standards [17] using the Analyzer CLD 88 sp (Eco Medics,
Duernten, Switzerland). It is considered low for children older than 5 years if <77 nL·min-1 (<233 ppb for
our setting) [18–20].
Nasal brushing and further use of the nasal epithelial cells
We obtain nasal epithelial cells by performing minimal invasive nasal brushings using interdental brushes
(IDB-G50 3 mm, Top Caredent, Zurich, Switzerland; elongated by attaching a 200-μL pipette tip with
parafilm). Cells are washed down from the brushes and used for further investigations as described below.
High-speed videomicroscopy
Epithelial cells of fresh brushings and of ALI cell cultures are recorded in sealed imaging chambers (Grace
Bio-Labs CoverWell™, GBL635051-40EA, Sigma-Aldrich, Buchs, Switzerland) on an inverted
transmitted light microscope (Olympus IX73) equipped with a high-speed C-MOS camera (FLIR 3.2 MP
Mono Grasshopper3 USB 3.0 Camera, Sony IMX252 chip). We usually record 10 fields of view (side
Clinical features – several of these:
 Persistent wet cough
 Situs anomalies
 Congenital cardiac defects
 Persistent rhinitis
 Chronic middle ear disease with or
   without hearing loss
 In term infant with neonatal upper/lower
   respiratory symptoms





Clinical features – at least 2 of 4:
 Unexplained neonatal respiratory 
   distress in term infant
 Year-round daily cough beginning 
   before 6 months of age
 Year-round daily nasal congestion 
   beginning before 6 months of age
 Organ laterally defect
ATS
Typical clinical features:
 Chronic productive cough
 Recurrent chronic rhinitis
 Recurrent otitis media
 Recurrent respiratory infections

















































FIGURE 1 Comparison of the three algorithms for PCD diagnosis. Adapted from the ERS [5] and the ATS [7] guidelines. Boxes and arrows marked
in blue indicate minimal requirements for a diagnosis. #nNO can only be used if performed with a chemiluminescence device according to a
standard protocol, provided the tested person is >5 years old and able to cooperate. A low nNO level should be repeated to ensure the low value is
not due to a respiratory infection [7]. ¶Testing for mutations in >12 disease-associated PCD genes, including deletion/duplication [7]. +Cell culture
at the air–liquid interface (ALI). §Further investigations (HSVM, immunofluorescence and TEM) are always preferably done by analysing the material
of the ALI cell culture. Fresh material is only used if the cell culture is not successful. fGenetic analysis is performed according to newest research
findings and the number of tested genes increases constantly. ATS: American Thoracic Society; ERS: European Respiratory Society; HSVM:
high-speed videomicroscopy; IF: immunofluorescence staining; nNO: nasal nitric oxide; PCD: primary ciliary dyskinesia; PCD-UNIBE: comprehensive
diagnostic centre at the University Children’s Hospital, Inselspital Bern, Switzerland; TEM: transmission electron microscopy.
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views and at least one top view) (bright field, 40× magnification, 300 frames per second, 640×480 pixels,
2 s) at room temperature (23–25°C). Ciliary beating pattern (CBP), beating amplitude, intracellular and
intercellular beating coordination, and ciliary beating frequency are analysed based on previously proposed
criteria [21, 22].
Typical clinical findings#
 Chronic productive cough
 Chronic rhinitis
 Recurrent otitis media
 Recurrent respiratory infections

























Class 2 TEM defect
(and e.g. pathological
IF or HSVME)
Class 1 TEM defect
and/or biallelic 




HSVM and IF normal
HSVM normal, protein in 
IF missing but strong 
clinical history
No biallelic 
pathogenic variants in 
PCD-associated genes








Nasal brushing and cell culture (ALI)¶





















TEM or genetics if 
not yet done
Consider retesting the 
patient in case of 
availability of new 
methods (e.g. new IF 
antibodies, new genetic 
methods/mutations)
FIGURE 2 Diagnostic algorithm of the PCD-UNIBE diagnostic centre at the University Children’s Hospital, Inselspital Bern, Switzerland. Explanation of
figures: rectangular boxes: investigations, oval boxes: decisions/considerations, round-edged rectangular boxes: results/outcome. The grey boxes
indicate basic methods which are used for each patient being referred to PCD-UNIBE for PCD diagnostics. #As a clinical screening, the PICADAR-Score
[16] may be useful. ¶Further investigations (HSVM, IF and TEM) are always preferably done using material obtained from ALI cell cultures. Consider
rebrushing if cell culture is not successful (especially for TEM); if rebrushing is not possible, fresh material is used. +If other results suggest PCD, we
recommend further investigations, e.g. RNA analysis or array-based comparative genomic hybridisation (array-CGH). ALI: air–liquid interface; HSVM:
high-speed videomicroscopy; IF: immunofluorescence staining; nNO: nasal nitric oxide; PCD: primary ciliary dyskinesia; PCD-UNIBE: comprehensive
diagnostic centre at the University Children’s Hospital, Inselspital Bern, Switzerland; TEM: transmission electron microscopy.
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Immunofluorescence staining
Immunofluorescence stainings are performed following a procedure derived from published protocols [13,
14, 23]. Our standard panel includes the staining for DNAH5, GAS8 and RSPH9 proteins. Upon suspicion
of incomplete DNAH5 staining, we also stain for DNAH9 and DNAH11. In case of a specific CBP in the
HSVM, we stain for other proteins (e.g. RSPH1, RSPH4a and RSPH3 in case of rotating cilia, DNAH11
in case of stiff beating with reduced amplitude or DNAH9 in case of distal stiffness). We cannot cover all
relevant proteins, but our standard panel includes the proteins affected by the most prevalent mutations
[13, 24]. For details of the staining protocols (including all available proteins), see supplementary material.
Transmission electron microscopy
Samples are processed according to standard protocols (see supplementary material for details). TEM
analysis and reporting follows the BEAT-PCD TEM criteria [12] with additional discrimination between
proximal and distal localisation.
ALI cell culture
Nasal epithelial cells of all patients are cultured using the PneumaCult media (Stemcell Technologies,
Saint-Egrève, France) following the manufacturer’s instruction with some adaptations partially published
previously [15] (for details see supplementary material).
Genetic analysis
For genetic analysis patients’ blood samples (collected in EDTA tubes) were sent to genetic testing centres
(Molecular and Genetic Diagnostic Lab, University Hospital Geneva or Human Genetics, Inselspital, Bern
University Hospital, Switzerland) to check for genetic variants in up to 46 PCD-associated genes by whole
exome sequencing (next-generation sequencing) (details on tested genes are given in supplementary tables
S1 and S3).
Statistics
We compared the ERS with the ATS algorithm, and both with our own PCD-UNIBE algorithm concerning
agreement and concordance on PCD diagnosis. Therefore, we used Cohen’s κ to assess interrater
agreement of the three algorithms [25], and we described concordance for the three algorithms using a
Venn diagram [26]. The analyses were done using Stata™ (Stata Statistical Software: Release 14;
StataCorp LP, College Station, TX, USA).
Results
Study population
We included 54 patients referred to our PCD-UNIBE centre from 10 Swiss hospitals between January
2018 and December 2020. For all of them we had sufficient information to define the diagnostic outcome
based on all three investigated algorithms. 24 patients (44%) were diagnosed with PCD based on at least
one of the three algorithms (table 1 for concordant cases, table 2 for discordant cases, supplementary table
S1 for detailed information of all cases). 30 patients were not diagnosed with PCD according to all three
algorithms (supplementary table S3). nNO measurement was performed in 46, HSVM in 54,
immunofluorescence in 53, TEM in 30 and genetics in 32 of 54 patients. Supplementary table S4
summarises the performed investigations.
Diagnostic outcome
We compared the diagnostic outcome between the ERS, the ATS and the PCD-UNIBE algorithms for all
patients. Out of 54 patients, 46 had a concordant outcome according to all three algorithms: 16 patients
with confirmed PCD (table 1) and 30 patients with excluded PCD (supplementary table S3). We found
different outcomes for eight out of the 54 patients (15%) (table 2). Low nNO levels led to a PCD
diagnosis for five patients (patients 15–19) according to the ATS algorithm only. Patient 14 was diagnosed
with PCD according to the ERS and the PCD-UNIBE (suggestive HSVM with rotating cilia after cell
culture) (Supplementary videos S1 and S2), but not according to the ATS algorithm (normal nNO
measurement and non-diagnostic TEM defect, refusing of genetic testing). Patient 9 was diagnosed
according to the PCD-UNIBE (missing DNAH9 in immunofluorescence, figure 3) and the ATS (low
nNO), but not the ERS algorithm (normal TEM, inconclusive HSVM, non-diagnostic genetics). Lastly,
patient 4 was diagnosed according to the PCD-UNIBE (missing DNAH9 in immunofluorescence (figure 3),
class 2 TEM defect (figure 4)), but neither according to the ERS nor the ATS algorithm (inconclusive
HSVM, non-diagnostic TEM and genetics).
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6 (267) 1.4 m Situs inversus
totalis
Chronic rhinitis
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21 (347) 65.0 f Positive family
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22 (348) 67.8 m Positive family
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Bold text indicates results leading to a diagnosis of PCD and the final diagnosis. ACMG: American College of Medical Genetics and Genomics; ALI: air–liquid interface; ATS: American Thoracic
Society; Array-CGH: array-based comparative genomic hybridisation; ERS: European Respiratory Society; f: female; HSVM: high-speed videomicroscopy; IDA: inner dynein arm; IF:
immunofluorescence labelling; m: male; nNO: nasal nitric oxide; NRDS: neonatal respiratory distress syndrome; ODA: outer dynein arm; PCD: primary ciliary dyskinesia; PCD-UNIBE:
comprehensive diagnostic centre at the University Children’s Hospital, Inselspital Bern, Switzerland; TEM: transmission electron microscopy. #These are mean values for nNO for the right and left
side. The unit for nNO results at our centre is parts per billion (ppb). To obtain values in nL·min-1 the formula (ppb) × sampling flow rate (0.33 mL·min-1 for Ecomedics Analyzer CLD 88 sp) was
used as proposed in LEIGH et al. [18]. ¶: child <5 years old. +: cystic fibrosis not excluded by sweat test or genetic testing. §: single nNO measurement. f: nNO measurement during rhinitis. ##:
DNAH5, GAS8, RSPH9 and DNAH11 stained. ¶¶: remark about the costs: the costs were estimated based on costs that are billed for each method performed (for costs of each method see














































































































Non-diagnostic No likely pathogenic
or pathogenic variant





























14 (361) 23.6 F Chronic productive
cough
Chronic rhinitis
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Single discordant outcome highlighted in italic letters. Bold text indicates results leading to a diagnosis of PCD and the final diagnosis. ACMG: American College of Medical Genetics and
Genomics; ALI: air–liquid interface; ATS: American Thoracic Society; Array-CGH: array-based comparative genomic hybridisation; ERS: European Respiratory Society; f: female; HSVM: high-speed
videomicroscopy; IDA: inner dynein arm; IF: immunofluorescence labelling; m: male; nNO: nasal nitric oxide; NRDS: neonatal respiratory distress syndrome; ODA: outer dynein arm; PCD: primary
ciliary dyskinesia; PCD-UNIBE: comprehensive diagnostic centre at the University Children’s Hospital, Inselspital Bern, Switzerland; TEM: transmission electron microscopy. #: these are mean
values for nNO for the right and left side. The unit for nNO results at our centre is parts per billion (ppb). To obtain values in nL·min-1 the formula (ppb) × sampling flow rate (0.33 mL·min-1 for
Ecomedics Analyzer CLD 88 sp) was used as proposed in LEIGH et al. [18]. ¶: single nNO measurement. +: cystic fibrosis not excluded by sweat test or genetic testing. §: nNO measurement during
rhinitis. f: remark about the costs: the costs were estimated based on costs that are billed for each method performed (for costs of each method see supplementary table S2 and figure S1). The























Agreement and concordance between the algorithms
While there was substantial agreement between the ERS and the ATS (κ=0.72, 95% CI 0.53–0.92) as well
as between the ATS and the PCD-UNIBE algorithms (κ=0.73, 95% CI 0.53–0.92), the agreement between
the ERS and the PCD-UNIBE algorithm was almost perfect (κ=0.92, 95% CI 0.80–1.00) (table 3).
Figure 5 shows the concordance for the three algorithms for all cases diagnosed with PCD according to at
least one algorithm.
Discussion
Out of 54 patients included in this study, we found concordant diagnostic outcome according to all three
algorithms for 46 patients (85%, 30 without and 16 with PCD diagnosis) and discordant diagnostic
outcome for eight patients. Thus, for 15% of the patients the diagnosis differed between algorithms. The
agreement about the diagnosis was substantial for the ERS and the ATS as well as for the ATS and the
PCD-UNIBE algorithms, and it was almost perfect for the ERS and the PCD-UNIBE algorithms.
With our finding of 15% of discordant diagnostic outcomes, we can confirm the already previously
discussed theoretical differences between the ERS and the ATS algorithms [8, 10, 11], based on data from
a real-life setting. The five cases (patients 15–19) that were only diagnosed based on reduced nNO
according to the ATS algorithm support the doubts that nNO as sole investigation can diagnose PCD [2,
10, 28–30]. nNO has a sensitivity and specificity of >95% compared with TEM or genetic testing when
performed in children >5 years old with cystic fibrosis excluded [7, 18, 30]. However, a considerable risk
for false negative [5, 10, 17] and false positive results [10, 17, 30, 31] remains. Besides the five cases
diagnosed with PCD based on the ATS algorithm only (“false positive” compared with the ERS and
PCD-UNIBE algorithms), we also found two patients with a “false negative” diagnosis based on the ATS
algorithm (patients 4 and 14). Patient 14 was diagnosed by the ERS and PCD-UNIBE algorithms based on


























Tubulin DAPI DNAH9 Overlay
FIGURE 3 DNAH9 immunofluorescence staining of patients 4 and 9. Tubulin (green) is used as a reference,
since it is present along all side of the ciliary axoneme. Diamidino-2-phenylindole (DAPI, blue) marks the cell
nuclei. In patient number 4 DAPI staining was not successful; however, this does not affect the interpretation
of the results. The target protein DNAH9 (red) is expected to be present in the distal part of the axoneme and
is completely absent for both patients. The overlay of all three stainings confirms missing DNAH9 in both
patients.
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patient 4 was only diagnosed by the PCD-UNIBE (based on immunofluorescence and TEM), but not by
the ERS or ATS algorithms. We therefore strongly support the suggestion of SHAPIRO et al. [30] to adapt
the ATS algorithm and not use nNO as a sole investigation any longer.
Another important discussion within the PCD community has been the accuracy of HSVM for the PCD
diagnostics [5, 7, 21, 29, 32, 33]. It has been shown that HSVM has good sensitivity and specificity to
diagnose PCD when following standardised protocols [21] and has the advantage to provide a fast
visualisation of the dyskinesia. In our study, the PCD diagnosis of four patients (patients 2, 3, 5 and 14)
was mainly based on HSVM. For patients 3 and 5, genetics testing revealed biallelic mutations in the
DNAH11 gene, but the clinical significance of the variants was unknown (according to the classification
of the American College of Medical Genetics and Genomics (ACMG) [27]). For patient 2, only one
heterozygote pathological variant in the DNAH11 gene was found. For all three patients with unclear
DNAH11 mutations (all with a non-diagnostic TEM), the HSVM clearly showed a pathological beating
pattern and led to the diagnosis of PCD. The fourth patient (patient 14) also had a non-diagnostic TEM
but showed rotating cilia in the HSVM. Since we performed the HSVM with the fresh samples and with
FIGURE 4 Transmission electron microscopy (TEM) image showing orthogonally sectioned cilia of patient
4. The axonemes at the arrowheads show shortened or missing outer (ODA, >4 of 9 affected) and inner (IDA, >6
of 9 affected) dynein arms. Scale bar: 250 nm. Numerical analysis according to the published BEAT-PCD TEM
criteria [12] are: ODA missing: 26.7% (34.4% proximal, 18.3% distal). IDA missing: 19.2% (23.4% proximal, 12.4%
distal). Microtubular disorganisation: 1.6% missing peripheral tubuli. Central complex defect: 1% missing
central tubuli, transposition defect: 2.6%. Consistent ciliary orientation.
TABLE 3 Agreement between the different diagnostic algorithms assessed by κ statistics
+ +# + −¶ − + + − −§ Total agreement κ 95% CI
ERS & ATS 16 (30%) 1 (2%) 6 (11%) 31 (57%) 47 (87%) 0.72 0.53–0.92
ERS & PCD-UNIBE 17 (31%) 0 (0%) 2 (4%) 35 (65%) 52 (96%) 0.92 0.80–1.00
ATS & PCD-UNIBE 17 (31%) 5 (9%) 2 (4%) 30 (56%) 47 (87%) 0.73 0.53–0.92
ERS: European Respiratory Society; ATS: American Thoracic Society; PCD-UNIBE: comprehensive diagnostic
centre at the University Children’s Hospital, Inselspital Bern, Switzerland. #: both algorithms diagnosed PCD. ¶:
the algorithm listed first diagnosed PCD; the one listed second diagnosed no PCD. +: the algorithm listed first
diagnosed no PCD; the one listed second diagnosed PCD. §: none of the algorithms diagnosed PCD.
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the ALI cell culture or we repeat the nasal brushing at different time points, we can exclude secondary
dyskinesia. Omitting HSVM from the diagnostic algorithm may thus lead to false negative diagnoses in
cases with non-diagnostic TEM or unclear genetic results [5, 10, 21]. However, we agree that HSVM
requires a high level of expertise and further standardisation of HSVM protocols is urgently needed [5, 7,
21, 32, 33].
Immunofluorescence is not part of both the ERS and the ATS algorithm [5, 7]. However,
immunofluorescence is very specific and can be especially helpful in cases with normal ciliary ultrastructure
(e.g. DNAH11 mutations) [13, 34, 35] or only subtle defects (e.g. DNAH9 mutations) in TEM [13, 24, 35].
Furthermore, according to the BEAT-PCD TEM criteria [12] immunofluorescence can be used to confirm a
class 2 TEM defect. In our study, immunofluorescence was a key test in 12 patients (patients 2–6, 8, 9, 20–
24). Nine patients had missing DNAH11, two missing DNAH9 and one lacked several ODA proteins. In the
cases with missing DNAH9, immunofluorescence was the most important method for diagnosing PCD.
Considering the results of our study and taking into account that immunofluorescence requires less resources
compared to TEM [36], we see many advantages of implementing immunofluorescence as part of the
diagnostic workup and support SHOEMARK and colleagues [13] in their demand to include
immunofluorescence in a future diagnostic algorithm.
In our study, 44% of the included cases were diagnosed with PCD. This is a very high ratio compared to
other centres, which usually confirm PCD in roughly 10% of the investigated cases [16]. There are three
main reasons for this high prevalence: 1) our centre started in 2018 with a comprehensive approach, and as
a consequence several previously unclear, but highly suspicious, cases from before were initially worked
up (e.g. patients 1, 2, 8, 14, 16, 20–23); 2) there were two PCD families with three and four members
(patients 10–12 and 20–23), respectively, that also contributed to the high prevalence; and 3) we included
only cases with sufficient data to allow a final diagnosis on PCD based on all three algorithms. In our
daily diagnostic workup, we only perform as many tests as needed to decide on a diagnosis. This
implicates that we do not have results for all methods for every patient. Especially TEM and genetics are,
due to high costs, not carried out if a PCD diagnosis is highly unlikely based on our basic investigations.
This resulted in a selection bias towards PCD positive cases. The fact that we did not perform all methods
for every patient is a clear weakness of the study. For single cases, the result of an additional method could









FIGURE 5 Venn diagram of patients with diagnosed primary ciliary dyskinesia (PCD) by the three different PCD
diagnostic algorithms. Coloured circles represent the three different diagnostic algorithms. PCD-UNIBE
algorithm (red); ERS algorithm (green); ATS algorithm (blue). Numbers listed represent patients with confirmed
PCD; where circles overlap are common positive diagnosed PCD patients. 54 patients were included in the
study and 30 were diagnosed without PCD by all three algorithms. This diagram shows the 24 cases that were
diagnosed with PCD according to at least one algorithm. ATS: American Thoracic Society; ERS: European
Respiratory Society.
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testing, a genetic mutation could have been identified and a PCD diagnosis according to the ATS guideline
would be likely). Another weakness of the study is the small sample size. We could only include 54
patients, since we only had enough data for those to assess the diagnosis based on all algorithms. In order
to address the cost issue in more detail, we calculated the costs for each case diagnosed with PCD
(supplementary table S2). The costs for immunofluorescence and TEM reported here are higher than those
previously reported [13]. The reasons are higher prices for consumables and higher salaries in Switzerland
compared to other countries. Even though the diagnostics of PCD is quite costly, we are convinced that
from a long-term perspective these costs, including the costs for the genetics, are justified with regards to a
better understanding of the disease, to have the basics to develop causative and personalised treatments and
to provide the patients with as much information about their specific disease as possible.
Although two consensus PCD diagnostic algorithms were recently published, diagnostics of PCD evolved
quickly over the past few years, and most centres use their own updated and adapted diagnostic algorithm. In
this study, we compared two published algorithms and our own (PCD-UNIBE). Our algorithm uses the most
current diagnostic standards, including newer methods such as immunofluorescence and a standard use of
ALI cell culture [3, 13, 37], and follows the recently published BEAT-PCD TEM criteria [12]. In our study,
both immunofluorescence and ALI cell culture turned out to be crucial for many diagnoses. It is a clear
strength of our study that we were able to assess the impact of including these recently developed procedures
in our diagnostic algorithms by comparing our algorithm to currently existing guidelines. However, for those
newer methods it will be important to also have international consensus standards. This is already in progress
for immunofluorescence staining as part of BEAT-PCD [38] but is also needed for HSVM.
In 15% of the cases, the diagnostic outcome differed between the applied algorithms, leading to
contradictory diagnoses for many patients. This may have consequences, for instance false positive PCD
diagnoses can lead to psychological distress [39] and omission of specific treatments such as stem cell
transplantation [30, 31]. Furthermore, it is very important for the patients to know their accurate diagnosis
[39], and it can be crucial for claiming reimbursement of treatment costs by disability insurance (like in
Switzerland). Finally, with regard to the real disease-altering treatment options currently being studied (e.g.
CLEAN-PCD study, ClinicalTrials.gov Identifier: NCT02871778) it will be of great importance to know
the underlying genetic mutations. Furthermore, with potential causative treatments in the future, we already
now need to collect more data and gain a better understanding of the genotype–phenotype interactions.
Besides the knowledge that some mutations (e.g. CCDC39/40) are associated with a more severe [40, 41]
and some (e.g. DNAH9) with a milder [23, 42] disease course, we do not know a lot about differences in
disease course based on the genotypes. PCD is a heterogeneous, genetic disease requiring complex
diagnostics. Our study suggests that neither the ERS nor the ATS guidelines are sufficient for diagnosis; in
some cases, extended investigations are needed. Our study shows that immunofluorescence and cell culture
are important procedures in PCD diagnostics and should be additionally performed routinely. Diagnostic
algorithms need to be continuously adapted according to the newest methods available. A single
internationally accepted diagnostic algorithm would be an important step towards standardisation and
facilitation of PCD diagnostics.
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